“Rise in Generic Drug Development”
The expiration of patents for dapagliflozin is leading to the entry of generic drug manufacturers, resulting in increased availability of cost-effective alternatives. This trend is particularly pronounced in developing countries, where affordability is a key factor in medication accessibility. Generic versions are enabling wider distribution in regions with limited healthcare budgets, ensuring that more patients benefit from dapagliflozin's therapeutic effects. This shift is also fostering competition among manufacturers, contributing to reduced treatment costs and enhancing the reach of sodium-glucose co-transporter-2 (SGLT-2) inhibitors in global markets.
